Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 932-940

  Yamaki, Ei ^a   Yajima, Toshiki ^a   Kosaka, Takayuki ^a   Mogi, Akira ^a   Tanaka, Shigebumi ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cis diamminedichloroplatinum(II); Extracellular signal regulated kinase; Malignant pleural mesothelioma; Matrix metalloproteinase 1; Podoplanin

Indexed keywords

CISPLATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PODOPLANIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STABLE EXPRESSION; SURVIVAL RATE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION; HUMANS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHENOTYPE; TUMOR BURDEN;

EID: 84872827805     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2225     Document Type: Article

References (36)

1. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L and van Meerbeeck J: Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5: 136-147, 2008.
2. Wicki A and Christofori G: The potential role of podoplanin in tumour invasion. Br J Cancer 96: 1-5, 2007. (Pubitemid 46094630)
3. Ramirez MI, Millien G, Hinds A, Cao Y, Seldin DC and Williams MC: T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol 256: 61-72, 2003. (Pubitemid 36332205)
4. Schacht V, Ramirez MI, Hong YK, et al: T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22: 3546-3556, 2003. (Pubitemid 36898332)
5. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al: Angiosar-comas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154: 385-394, 1999. (Pubitemid 29094089)
6. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T and Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 26: 195-200, 2005. (Pubitemid 41379745)
7. Martin-Villar E, Scholl FG, Gamallo C, et al: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113: 899-910, 2005. (Pubitemid 40096869)
8. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166: 913-921, 2005. (Pubitemid 40315647)
9. Shibahara J, Kashima T, Kikuchi Y, Kunita A and Fukayama M: Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 448: 493-499, 2006.
10. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D and Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272, 2006.
11. Kimura N and Kimura I: Podoplanin as a marker for mesothelioma. Pathol Int 55: 83-86, 2005. (Pubitemid 40343728)
12. Ordonez NG: Podoplanin: a novel diagnostic immunohisto-chemical marker. Adv Anat Pathol 13: 83-88, 2006. (Pubitemid 44350516)
13. Hinterberger M, Reineke T, Storz M, Weder W, Vogt P and Moch H: D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 20: 248-255, 2007. (Pubitemid 46422180)
14. Padgett DM, Cathro H P, Wick MR and Mills SE: Podoplanin is a better immunohistochemical marker for sarcomatoid mesothe-lioma than calretinin. Am J Surg Pathol 32: 123-127, 2008.
15. Mimura T, Ito A, Sakuma T, et al: Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiag-nostic markers for pleural mesothelioma. Cancer 109: 933-938, 2007. (Pubitemid 46333535)
16. Marchevsky AM: Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 132: 397-401, 2008. (Pubitemid 351328814)
17. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al: Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26: 354-360, 2008. (Pubitemid 351171684)
18. Horiguchi A, Ito K, Sumitomo M, Kimura F, Asano T and Hayakawa M: Intratumoral lymphatics and lymphatic invasion are associated with tumor aggressiveness and poor prognosis in renal cell carcinoma. Urology 71: 928-932, 2008.
19. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T and Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 111: 483-488, 2006.
20. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S and Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119: 4541-4553, 2006. (Pubitemid 44830653)
21. Kunita A, Kashima TG, Morishita Y, et al: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170: 1337-1347, 2007. (Pubitemid 47339340)
22. Deroanne CF, Hamelryckx D, Ho TT, et al: Cdc42 downregulates MMP-1 expression by inhibiting the ERK1/2 pathway. J Cell Sci 118: 1173-1183, 2005. (Pubitemid 40528688)
23. Zeng ZS, Shu WP, Cohen AM and Guillem JG: Matrix metal-loproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 8: 144-148, 2002. (Pubitemid 34101470)
24. Tutton MG, George ML, Eccles SA, Burton S, Swift RI and Abulafi AM: Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 107: 541-550, 2003. (Pubitemid 37296113)
25. Klominek J, Baskin B and Hauzenberger D: Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis 16: 529-539, 1998. (Pubitemid 29009588)
26. Mueller L, Goumas FA, Himpel S, Brilloff S, Rogiers X and Broering DC: Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer Lett 250: 329-338, 2007. (Pubitemid 46529454)
27. Faried A, Faried LS, Kimura H, et al: RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 42: 1455-1465, 2006. (Pubitemid 43903150)
28. Spugnini E P, Cardillo I, Verdina A, et al: Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 12: 6133 - 6143, 2006. (Pubitemid 44703779)
29. Zhong J, Gencay MM, Bubendorf L, et al: ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and meso-thelial cells. J Cell Physiol 207: 540-552, 2006.
30. Gorelik E, Bere WW and Herberman RB: Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 33: 87-94, 1984. (Pubitemid 14223238)
31. Scholl FG, Gamallo C, Vilaró S and Quintanilla M: Identification of PA2.26 antigen as a novel cell-surface mucin-type glycopro-tein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 112: 4601-4613, 1999. (Pubitemid 30034809)
32. Suzuki-Inoue K, Kato Y, Inoue O, et al: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 282: 25993-26001, 2007. (Pubitemid 47443800)
33. Edwards JG, McLaren J, Jones JL, Waller DA and O'Byrne KJ: Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 88: 1553-1559, 2003. (Pubitemid 36713781)
34. Baker SJ and Reddy EP: Modulation of life and death by the TNF receptor superfamily. Oncogene 17: 3261-3270, 1998. (Pubitemid 29043978)
35. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004. (Pubitemid 38638846)
36. Lee S, Yoon S and Kim DH: A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resis-tant human ovarian cancer cells. Gynecol Oncol 104: 338-344, 2007. (Pubitemid 46135659)